Browse Category

TSXV:VZLA News 28 December 2025

Vizsla Silver Corp (VZLA) Stock Weekend Update: Silver’s Record Run, Fresh Analyst Targets, and What Investors Should Watch Before Monday’s Open

Vizsla Silver Corp (VZLA) Stock Weekend Update: Silver’s Record Run, Fresh Analyst Targets, and What Investors Should Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 2:38 a.m. ET, Market closed — Vizsla Silver Corp. (NYSE American: VZLA; TSX-V: VZLA) is heading into the final trading days of 2025 with momentum on its side after a strong Friday move that coincided with a powerful year-end bid in precious metals and a holiday-thinned U.S. equity session. With U.S. exchanges closed for the weekend, investors are now in “prep mode” for Monday’s reopen—balancing a surging silver tape, a light-liquidity year-end market backdrop, and a string of recent analyst notes that have put new price targets on the stock. VZLA stock price: where Vizsla
28 December 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop